Financial Performance Highlights

  • Total Revenue from Operations: ₹22,756 million (33% YoY growth from ₹17,163 million)
  • Profit Before Tax: ₹2,522 million (61% growth from ₹1,564 million)
  • Profit After Tax: ₹1,875 million (62% growth from ₹1,157 million)
  • Basic and Diluted EPS: ₹75.01 (up from ₹46.30)
  • Dividend Recommended: ₹36 per equity share (₹900 million total, up from ₹32 per share)
  • Cash and Cash Equivalents: ₹4,477 million (down from ₹5,361 million)
  • Total Equity: ₹8,728 million (up from ₹7,704 million)

Business Segment Performance

Oncology Business

  • Revenue: ₹16,101 million (44% YoY growth)
  • Key brands: Tagrisso (osimertinib), Imfinzi (durvalumab), Enhertu (trastuzumab deruxtecan)
  • Advanced to top 2 oncology companies in India by revenue
  • 11 regulatory approvals secured for medicines and indications

Biopharmaceuticals Business

  • Revenue: ₹5,243 million (7.2% YoY growth)
  • Key brands: Brilinta (ticagrelor), Lokelma (sodium zirconium cyclosilicate), Fasenra (benralizumab), Breztri
  • Strategic partnership with Sun Pharma for Lokelma distribution

Rare Disease Business

  • Revenue: ₹215 million (7x growth)
  • Key products: Koselugo (selumetinib) for NF1, Soliris (eculizumab) for aHUS and PNH

Operational Highlights and Significant Events

  • Exited manufacturing operations at Bengaluru facility as part of global manufacturing network review
  • Restructuring Provision: ₹139.7 million recognized
  • Exceptional Items: ₹52.5 million related to closure costs
  • Assets Classified as Held for Sale: ₹77.4 million
  • Total employee strength: 760 as of March 31, 2026 (802 in previous year)
  • Impact of Labour Code implementation recognized as past service cost of ₹195.8 million

Annual General Meeting Details

  • Date: August 10, 2026
  • Time: 3:00 PM IST
  • Mode: Video Conferencing/Other Audio Visual Means
  • Record Date for Dividend: July 31, 2026

Agenda Items

1. Adoption of audited financial statements and reports

2. Declaration of dividend of ₹36 per share

3. Re-appointment of Ms. Bhavana Agrawal as Director retiring by rotation

4. Appointment of M/s. BSR & Co. LLP as Statutory Auditors for 5 years

5. Re-appointment of Ms. Shilpa Divekar Nirula as Independent Director

Financial Position and Ratios

  • Current Ratio: 1.8 (FY25: 1.9)
  • Debt-Equity Ratio: 12.7% (FY25: 4.6%) - increased due to new lease liabilities
  • Return on Equity: 22.8% (FY25: 15.6%)
  • Inventory Turnover Ratio: 1.8 (FY25: 2.5)
  • Net Profit Ratio: 8.2% (FY25: 6.7%)

Related Party Transactions

  • Purchases from Related Parties: ₹18,398.5 million (mainly from AstraZeneca UK Limited and AstraZeneca AB, Sweden)
  • Sales to Related Parties: ₹1,167.0 million (clinical trials and marketing support services)
  • Trade Payables to Related Parties: ₹6,098.4 million (FY25: ₹2,891.5 million)

Legal and Contingent Matters

  • NPPA Demand Notice: ₹1,573.9 million alleged overcharging for anti-cancer drug (pending before Delhi High Court)
  • Taxation Matters: ₹1,212.3 million in contingent liabilities
  • BBMP Improvement Charges: ₹70.8 million demand (regrouped to current liabilities)
  • Arbitration proceedings with NHAI regarding land acquisition compensation

Corporate Governance and Shareholding

  • Board comprises 6 Directors (4 Non-Executive, 3 Independent)
  • Promoter Holding: 75% (AstraZeneca Pharmaceuticals AB)
  • Public Holding: 25%
  • CSR Expenditure: ₹33.8 million (2% of average net profit)
  • Auditors: M/s. Price Waterhouse & Co. Chartered Accountants LLP (tenure ending), proposed M/s. BSR & Co. LLP

Forward-Looking Statements

The Management Discussion & Analysis contains forward-looking statements about the company's objectives, projections, and expectations. Actual results may differ materially due to economic conditions, government regulations, tax laws, and other incidental factors.